This article is more than 5 years old. Information may no longer be current.
Remission, minimal disease activity may be possible with TNFi for some patients with axial PsA
Some patients with axial psoriatic arthritis were able to achieve minimal disease activity and remission with tumor necrosis factor inhibitors, according to the results of a study.
Researchers recruited 58 patients with predominant axial psoriatic arthritis and a median disease duration of 8.05 years. Dactylitis was present in 17 patients, and 12 patients had enthesitis. Investigators found 13 patients were HLA-B27-positive.
Patients received either adalimumab, etanercept or golimumab and were assessed according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Composite Psoriatic Disease Activity Index (CPDAI) and Disease Activity Index for Psoriatic Arthritis (DAPSA). At baseline, all patients had a CPDAI of greater than 4 and a DAPSA score of greater than 3.3. No patient had minimal disease activity.
At 12 months, 15 of the remaining 48 patients achieved BASDAI 50. Investigators found 17 patients achieved a CPDAI of less than 4 and 11 patients had a DAPSA of 3.3 or less. Eleven patients met partial remission criteria, and 24 patients had minimal disease activity. Men were more likely to respond to treatment, with an odds ratio (OR) of 3.4. An OR of 21 was observed for age, and a low Health Assessment Questionnaire (HAQ) score had an OR of 15.23. Disease duration had an OR of 3.4. No predictors for achieving BASDAI 50 were found, and only HAQ scores were predictive of partial remission. – by Shirley Pulawski
Disclosure: The researchers report no relevant financial disclosures.